Roche Holding announced that the U.S. FDA has granted its drug, Tecentriq, priority review for the first-line treatment of a type of lung cancer.
Tecentriq is currently FDA approved for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who have disease progression following chemotherapy. The FDA has now granted priority review for Tecentriq in combination with Avastin (bevacizumab), paclitaxel and chemotherapy, for the initial treatment of people with metastatic non-squamous NSCLC.
The FDA is expected to make a decision on approval by September 5, 2018.
Read the press release